GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 025250 Name of the Signatory :- HARISH KUBERDesignation :- Company Secretary and Compliance Officer Glenmark Pharma gets USFDA nod for prostate cancer treatment drug
Drug firm Glenmark Pharmaceuticals on Thursday said it has received final approval from the US health regulator for Abiraterone Acetate tablets, used Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Abiraterone Acetate Tablets USP, 250 mg
US FDA highlights Glenmark's inability to probe batch failures in Baddi warning letter
In its warning letter, the US FDA said the company failed to timely recall and remake the topical cream.The Baddi facility had received a warning earlier this month after an inspection of the plant in April GLENMARK PHARMACEUTICALS LTD. - 532296 - Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2019
Enclosed please find herewith the copy of the certificate issued by M/s. Savita Jyoti Associates, Company Secretaries under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 30th September, 2019 GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September,2019
Enclosed please find herewith the Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 30th September, 2019. Please take the same on records. Glenmark's generic drug to treat multiple sclerosis gets tentative nod from USFDA
Glenmark Pharmaceuticals on Wednesday said it has received tentative nod from the US health regulator for dimethyl fumarate delayed-release capsules u Sameer Narayan on Titan, Zee, Glenmark, auto
One has to see auto micro markets, segments that are uptrading. Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives tentative ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives tentative ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg